White House Denies Trump Using Obesity Drug in Compassionate Use Program
Summary
The White House said President Donald Trump was not given an experimental obesity drug called retatrutide through the FDA’s compassionate use program. A news report suggested a patient receiving the drug matched President Trump’s age, but the White House denied it and called the report incorrect.Key Facts
- The FDA’s compassionate use program allows some patients to try drugs that are not yet fully approved.
- STAT News reported that a 79-year-old man with obesity and related health problems received the drug retatrutide from Eli Lilly.
- The report suggested this patient might be President Donald Trump, who recently turned 80.
- The White House strongly denied that President Trump was the patient.
- White House spokesperson Kush Desai called the report baseless speculation.
- The White House responded on social media to clarify the patient was not President Trump.
- Newsweek contacted Eli Lilly and the Department of Health and Human Services for comments.
- The article about this situation is still developing, and further updates are expected.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.